Cancer Research Annual Meeting 2010 Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Agbunag, C.
Right arrow Articles by Bar-Sagi, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Agbunag, C.
Right arrow Articles by Bar-Sagi, D.
[Cancer Research 64, 5659-5663, August 15, 2004]
© 2004 American Association for Cancer Research

Regular Articles

Oncogenic K-ras Drives Cell Cycle Progression and Phenotypic Conversion of Primary Pancreatic Duct Epithelial Cells

Cristina Agbunag1 and Dafna Bar-Sagi1,2

1 Graduate Program in Molecular and Cellular Biology, 2 Department of Molecular Genetics and Microbiology, State University of New York at Stony Brook, Stony Brook, New York

We have established a primary pancreatic duct epithelial cell culture (PDEC) system to investigate the relationship between oncogenic activation of K-ras and pancreatic ductal tumorigenesis. We have found that the acute introduction of physiological levels of oncogenic K-ras (K-rasV12) into quiescent PDECs stimulates S-phase entry and induces a pronounced increase in cell size. Both effects are dependent on the functional integrity of the phosphatidylinositol 3'-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling pathway. In addition, K-rasV12 promotes the loss of epithelial E-cadherin and the gain of mesenchymal N-cadherin in PDEC. Our observations indicate that the oncogenic activation of K-ras is sufficient to elicit mitogenic and morphogenic responses in pancreatic ductal cells and hence is likely to play an instructive role in the initiation of pancreatic ductal adenocarcinoma.




This article has been cited by other articles:


Home page
 MutagenesisHome page
M. Porta, T. Lopez, J. Pumarega, M. Jariod, M. Crous-Bou, E. Marco, J. Rifa, J. O. Grimalt, N. Malats, F. X. Real, et al.
In pancreatic ductal adenocarcinoma blood concentrations of some organochlorine compounds and coffee intake are independently associated with KRAS mutations
Mutagenesis, November 1, 2009; 24(6): 513 - 521.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
M. P. Quinlan, S. E. Quatela, M. R. Philips, and J. Settleman
Activated Kras, but Not Hras or Nras, May Initiate Tumors of Endodermal Origin via Stem Cell Expansion
Mol. Cell. Biol., April 15, 2008; 28(8): 2659 - 2674.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
N. K. Prasad, M. Tandon, S. Badve, P. W. Snyder, and H. Nakshatri
Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover
Carcinogenesis, January 1, 2008; 29(1): 25 - 34.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Jin, S. Park, D. Z. Ewton, and E. Friedman
The Survival Kinase Mirk/Dyrk1B Is a Downstream Effector of Oncogenic K-ras in Pancreatic Cancer
Cancer Res., August 1, 2007; 67(15): 7247 - 7255.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
B. Rubio-Viqueira, H. Mezzadra, M. E. Nielsen, A. Jimeno, X. Zhang, C. Iacobuzio-Donahue, A. Maitra, M. Hidalgo, and S. Altiok
Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays
Mol. Cancer Ther., February 1, 2007; 6(2): 515 - 523.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y.-W. E. Chang, J. W. Marlin, T. W. Chance, and R. Jakobi
RhoA Mediates Cyclooxygenase-2 Signaling to Disrupt the Formation of Adherens Junctions and Increase Cell Motility
Cancer Res., December 15, 2006; 66(24): 11700 - 11708.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
T. B. Deramaudt, M. Takaoka, R. Upadhyay, M. J. Bowser, J. Porter, A. Lee, B. Rhoades, C. N. Johnstone, R. Weissleder, S. R. Hingorani, et al.
N-Cadherin and Keratinocyte Growth Factor Receptor Mediate the Functional Interplay between Ki-RASG12V and p53V143A in Promoting Pancreatic Cell Migration, Invasion, and Tissue Architecture Disruption.
Mol. Cell. Biol., June 1, 2006; 26(11): 4185 - 4200.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
A. F. Hezel, A. C. Kimmelman, B. Z. Stanger, N. Bardeesy, and R. A. DePinho
Genetics and biology of pancreatic ductal adenocarcinoma.
Genes & Dev., May 15, 2006; 20(10): 1218 - 1249.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
N. Smakman, D. J. M. van den Wollenberg, I. H. M. B. Rinkes, R. C. Hoeben, and O. Kranenburg
Sensitization to Apoptosis Underlies KrasD12-Dependent Oncolysis of Murine C26 Colorectal Carcinoma Cells by Reovirus T3D
J. Virol., December 1, 2005; 79(23): 14981 - 14985.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.